Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,381,001
  • Shares Outstanding, K 58,741
  • Annual Sales, $ 43,100 K
  • Annual Income, $ -99,530 K
  • 60-Month Beta 1.69
  • Price/Sales 30.59
  • Price/Cash Flow N/A
  • Price/Book 3.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.53
  • Number of Estimates 7
  • High Estimate -0.26
  • Low Estimate -0.88
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -8.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.54 +42.14%
on 09/04/20
23.90 -1.63%
on 09/18/20
+2.31 (+10.90%)
since 08/18/20
3-Month
16.54 +42.14%
on 09/04/20
25.56 -8.02%
on 07/09/20
+2.79 (+13.47%)
since 06/18/20
52-Week
9.18 +156.10%
on 03/16/20
25.56 -8.02%
on 07/09/20
+8.64 (+58.10%)
since 09/18/19

Most Recent Stories

More News
CRISPR Stocks: Buy or Trade?

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

VRTX : 265.39 (-2.24%)
SGMO : 10.82 (+0.37%)
EDIT : 33.90 (+3.67%)
NTLA : 23.51 (+4.72%)
CRSP : 85.90 (+0.89%)
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 11.59% and 72.13%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?...

NTLA : 23.51 (+4.72%)
Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2%

Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

AGEN : 5.18 (-0.19%)
NTLA : 23.51 (+4.72%)
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.

IRWD : 10.00 (+0.91%)
REGN : 555.24 (-1.73%)
GILD : 65.05 (+0.02%)
ABIO : 5.18 (+2.17%)
NTLA : 23.51 (+4.72%)
PHAS : 3.65 (+3.69%)
Regeneron Expands Deal With Intellia for Hemophilia Treatments

Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.

REGN : 555.24 (-1.73%)
SNY : 52.44 (+0.71%)
GILD : 65.05 (+0.02%)
NTLA : 23.51 (+4.72%)
Stocks Still Rising to Begin June

Stocks Still Rising to Begin June

EA : 125.90 (+0.51%)
ICE : 99.21 (-0.75%)
CHWY : 53.00 (-2.61%)
VSAT : 35.11 (-1.18%)
ATHM : 96.70 (+0.67%)
CURO : 7.38 (-2.25%)
HAIN : 35.38 (+0.43%)
VIRT : 26.94 (+0.15%)
DG : 208.10 (+2.26%)
FLO : 23.51 (+0.38%)
W : 290.09 (+7.70%)
BIG : 44.77 (-1.13%)
CWH : 30.06 (-2.94%)
GPK : 14.10 (-0.70%)
TNK : 12.14 (-0.41%)
VGR : 10.11 (-1.08%)
NTLA : 23.51 (+4.72%)
REGN : 555.24 (-1.73%)
Intellia Therapeutics Inc (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics Inc (NTLA) delivered earnings and revenue surprises of -61.54% and -46.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?...

NTLA : 23.51 (+4.72%)
NASDAQ Jumps Over 1% as Tech Sparks Late Rally

NASDAQ Jumps Over 1% as Tech Sparks Late Rally

BNFT : 11.34 (+1.70%)
HLIT : 5.72 (+3.25%)
ZYXI : 17.20 (-0.12%)
DPZ : 397.59 (+0.64%)
SPOT : 233.89 (-0.18%)
VIRT : 26.94 (+0.15%)
CLX : 208.15 (+0.63%)
CNX : 11.37 (+2.62%)
YUMC : 51.30 (-1.37%)
STNG : 12.85 (-2.95%)
EDIT : 33.90 (+3.67%)
NTLA : 23.51 (+4.72%)
BLUE : 56.66 (+1.32%)
AMZN : 2,954.91 (-1.79%)
AAPL : 106.84 (-3.17%)
NFLX : 469.96 (-0.05%)
MSFT : 200.39 (-1.24%)
DIS : 128.63 (-1.22%)
LYFT : 30.59 (-2.08%)
UBER : 37.12 (+0.16%)
GRUB : 69.25 (+0.61%)
SQ : 145.01 (-0.43%)
BMY : 59.27 (-0.22%)
HLT : 89.64 (-1.68%)
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food...

NVS : 90.94 (-0.03%)
NTLA : 23.51 (+4.72%)
Horrible Week Finally Comes to an End

Horrible Week Finally Comes to an End

TQQQ : 116.48 (-3.86%)
CURE : 62.61 (-0.22%)
SGMO : 10.82 (+0.37%)
TTD : 435.75 (+1.63%)
JPM : 98.35 (-0.21%)
ACCO : 6.12 (-1.29%)
NTLA : 23.51 (+4.72%)
GH : 102.50 (+1.74%)
CRSP : 85.90 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade NTLA with:

Business Summary

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with...

See More

Key Turning Points

2nd Resistance Point 24.47
1st Resistance Point 23.99
Last Price 23.51
1st Support Level 22.94
2nd Support Level 22.37

See More

52-Week High 25.56
Last Price 23.51
Fibonacci 61.8% 19.30
Fibonacci 50% 17.37
Fibonacci 38.2% 15.44
52-Week Low 9.18

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar